UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 434

Sortiert nach

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer

Annals of oncology, 2018-01, Vol.29 (1), p.139-144

2018

Link zum Volltext

Verfügbarkeit prüfen

Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials

Annals of oncology, 2016-06, Vol.27 (6), p.1068-1074

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer

Annals of oncology, 2019-03, Vol.30 (3), p.495-495

2019

Link zum Volltext

Verfügbarkeit prüfen

PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers

ESMO open, 2021-10, Vol.6 (5), p.100230-100230, Article 100230

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer

Investigational new drugs, 2015-08, Vol.33 (4), p.977-984

2015

Link zum Volltext

Verfügbarkeit prüfen

The sequential radiographic effects of preoperative chemotherapy and (chemo)radiation on tumor anatomy in patients with localized pancreatic cancer

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2020-11, Vol.20, p.S18-S18

2020

Link zum Volltext

Verfügbarkeit prüfen

Frailty is adversely associated with quality of life in patients with newly diagnosed pancreatic cancer

Journal of geriatric oncology, 2013-10, Vol.4, p.S78-S78

2013

Link zum Volltext

Verfügbarkeit prüfen

P-27 Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high or mismatch repair-deficient stage IV colorectal cancer

Annals of oncology, 2022-06, Vol.33, p.S256-S257

2022

Link zum Volltext

Verfügbarkeit prüfen

sTNF-R1 and other cytokines associated with symptom burden related to chemotherapy in patients with colorectal cancer

Brain, behavior, and immunity, 2011, Vol.25, p.S197-S197

2011

Link zum Volltext

Verfügbarkeit prüfen

Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF -Mutated Colorectal Cancer

Clinical colorectal cancer, 2014-09, Vol.13 (3), p.164-171

2014

Link zum Volltext

Verfügbarkeit prüfen

597TiP A phase Ib study on a TRPV6-inhibitor, SORC13 in patients with advanced solid tumours

Annals of oncology, 2020-09, Vol.31, p.S499-S500

2020

Link zum Volltext

Verfügbarkeit prüfen

LBA7 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the KEYNOTE-177 study Asia subgroup

Annals of oncology, 2023-11, Vol.34, p.S1502-S1503

2023

Link zum Volltext

Verfügbarkeit prüfen

LBA32 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study

Annals of oncology, 2023-10, Vol.34, p.S1271-S1272

2023

Link zum Volltext

Verfügbarkeit prüfen

P-81 Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1–positive metastatic colorectal cancer (mCRC)

Annals of oncology, 2022-06, Vol.33, p.S277

2022

Link zum Volltext

Verfügbarkeit prüfen

669P Body composition and clinical outcomes in men with metastatic castration-resistant prostate cancer (mCRPC)

Annals of oncology, 2020-09, Vol.31, p.S538-S538

2020

Link zum Volltext

Verfügbarkeit prüfen

O-8 Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer

Annals of oncology, 2021-07, Vol.32, p.S220-S221

2021

Link zum Volltext

Verfügbarkeit prüfen

A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4001-4001

2010

Link zum Volltext

Verfügbarkeit prüfen

Corrections to “Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer”

Annals of oncology, 2019-03, Vol.30 (3), p.495-495

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

Drug design, development and therapy, 2015-01, Vol.9 (default), p.5075-5086

2015

Link zum Volltext

Verfügbarkeit prüfen

CLINICIAN SAFETY

The Psychiatric clinics of North America, 1999-12, Vol.22 (4), p.923-940

1999

Link zum Volltext

Verfügbarkeit prüfen

328 POSTER Phase II study of MTOR-inhibitor RAD001 and erlotinib for advanced, gemcitabine-refractory pancreatic cancer

European journal of cancer supplements, 2008, Vol.6 (12), p.104-104

2008

Link zum Volltext

Verfügbarkeit prüfen

Rate Measurements by the Pulsed-Accelerated-Flow Method

Analytical chemistry (Washington), 1997-02, Vol.69 (3), p.431-438

1997

Link zum Volltext

Verfügbarkeit prüfen

Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials super()

Annals of oncology, 2016-06, Vol.27 (6), p.1068-1074

2016

Link zum Volltext

Verfügbarkeit prüfen

Non-metal redox kinetics: hypochlorite and hypochlorous acid reactions with sulfite

Inorganic chemistry, 1989-03, Vol.28 (6), p.986-993

1989

Link zum Volltext

Verfügbarkeit prüfen

Self-report of neuropathy from oxaliplatin-based regimens in the treatment of colorectal cancer: With or without bevacizumab

Journal of clinical oncology, 2011-02, Vol.29 (4_suppl), p.551-551

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 434

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(393)
Mit Volltextzugriff
(368)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(264)
Life Sciences & Biomedicine
(250)
Humans
(244)
Female
(149)
Biological And Medical Sciences
(114)
Middle Aged
(102)
Male
(98)
Medical Sciences
(92)
Aged
(80)
Adult
(76)
Animals
(68)
Endocrinology & Metabolism
(36)
Cells, Cultured
(35)
Atherosclerosis
(34)
General & Internal Medicine
(34)
Radionuclide Imaging
(34)
Cardiovascular System & Cardiology
(30)
Biochemistry & Molecular Biology
(29)
Fundamental And Applied Biological Sciences. Psychology
(29)
Medicine, General & Internal
(29)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer

Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer

PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers

Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer

The sequential radiographic effects of preoperative chemotherapy and (chemo)radiation on tumor anatomy in patients with localized pancreatic cancer

Frailty is adversely associated with quality of life in patients with newly diagnosed pancreatic cancer

P-27 Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high or mismatch repair-deficient stage IV colorectal cancer

sTNF-R1 and other cytokines associated with symptom burden related to chemotherapy in patients with colorectal cancer

Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF -Mutated Colorectal Cancer

597TiP A phase Ib study on a TRPV6-inhibitor, SORC13 in patients with advanced solid tumours

LBA7 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the KEYNOTE-177 study Asia subgroup

LBA32 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study

P-81 Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1–positive metastatic colorectal cancer (mCRC)

669P Body composition and clinical outcomes in men with metastatic castration-resistant prostate cancer (mCRPC)

O-8 Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer

A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC)

Corrections to “Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer”

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

CLINICIAN SAFETY

328 POSTER Phase II study of MTOR-inhibitor RAD001 and erlotinib for advanced, gemcitabine-refractory pancreatic cancer

Rate Measurements by the Pulsed-Accelerated-Flow Method

Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials super()

Non-metal redox kinetics: hypochlorite and hypochlorous acid reactions with sulfite

Self-report of neuropathy from oxaliplatin-based regimens in the treatment of colorectal cancer: With or without bevacizumab

Suchergebnisse filtern